Welcome to our dedicated page for Accelerate Diagnostics news (Ticker: AXDX), a resource for investors and traders seeking the latest updates and insights on Accelerate Diagnostics stock.
Accelerate Diagnostics, Inc. (AXDX) generates news that spans product development in rapid in vitro diagnostics, regulatory milestones, financial performance, and significant corporate restructuring events. Company press releases describe a focus on solutions for antibiotic resistance and sepsis, with updates on platforms such as the Accelerate Pheno system, Accelerate PhenoTest ae BC kit, the FDA-cleared Accelerate Arc ae system and BC kit, and the development-stage Accelerate WAVE ae system.
News coverage frequently highlights clinical and regulatory progress. For example, the company has announced 510(k) clearance of the Accelerate Arc system and BC kit and the submission of the Accelerate WAVE system and Gram-negative positive blood culture test kit to the U.S. Food and Drug Administration for 510(k) clearance. Other releases describe successful pre-clinical and clinical trial milestones for the WAVE system, including performance data compared to broth microdilution reference methods and time-to-result metrics intended to support same-shift antimicrobial susceptibility reporting.
Financial news from Accelerate Diagnostics includes quarterly and full-year results, with details on net sales, gross margin, operating expenses, research and development spending, and net loss. The company has also reported on financing activities, such as debt issuances and debtor-in-possession financing commitments, as well as decisions about investor communications, including changes to its practice of hosting regular earnings conference calls.
A major theme in recent news is the companys Chapter 11 restructuring. Press releases and related SEC filings describe the voluntary Chapter 11 petitions filed in the United States Bankruptcy Court for the District of Delaware, a court-supervised sale process under Section 363 of the Bankruptcy Code, and an asset purchase agreement with an affiliate of Indaba Capital Management, L.P. Subsequent updates discuss court approval of the sale transaction, amendments to the asset purchase agreement, and confirmation of a Chapter 11 Plan of Liquidation that provides for cancellation of existing equity interests.
Visitors to this news page can review historical announcements on product clearances, trial results, financial performance, capital structure changes, and the progression of the Chapter 11 cases and asset sale. This context helps investors and observers understand how Accelerate Diagnostics diagnostic platforms and corporate structure have evolved over time.
Accelerate Diagnostics (NASDAQ:AXDX) has received FDA clearance for enhancements to its Accelerate Pheno® system. This upgrade improves antimicrobial susceptibility testing (AST) performance, particularly for treating Pseudomonas aeruginosa infections. The new tests expand the system's AST menu, aiding clinicians in personalized patient care. CEO Jack Phillips emphasized the company's commitment to continual improvement and announced upcoming product releases, including the Accelerate PhenoAST BC GN kit. These advancements aim to reduce testing time significantly, improving patient outcomes.
Accelerate Diagnostics (NASDAQ:AXDX) and BioCheck, Inc. announced FDA Emergency Use Authorization for their individual SARS-CoV-2 IgM and IgG Test Kits. This follows the EUA approval of their fully automated MS-Fast instrument. Accelerate will market and support this serology platform, which processes human serum samples in 30 minutes to detect antibodies indicating COVID-19 infection. The tests target the S1 protein to minimize false positives. The CEO emphasized the importance of flexible testing solutions as serology testing plays a crucial role in combating COVID-19.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) appointed Dr. Nedal Safwat as Chief Strategy Officer, effective immediately. Dr. Safwat, who previously held key roles at BioMerieux, is anticipated to lead the new product strategy and long-term growth initiatives. CEO Jack Phillips expressed confidence in Dr. Safwat's expertise in microbiology diagnostics. Accelerate Diagnostics focuses on combatting antibiotic resistance and sepsis, with its FDA-cleared Accelerate Pheno® system enhancing clinical outcomes by improving antibiotic therapy decisions.
Accelerate Diagnostics has received Emergency Use Authorization (EUA) from the FDA for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and the MS-Fast instrument. This collaboration enables Accelerate Diagnostics to market a serology-based platform that processes human serum samples in just 30 minutes. The test targets the S1 protein of the coronavirus, minimizing false positives. Leadership emphasizes its importance for COVID-19 demographic surveillance and potential global use. This marks a significant step toward wider adoption of antibody testing.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) reported its Q2 2020 financial results on August 6, showing a 17% increase in net sales to $2.1 million, compared to $1.8 million in Q2 2019. The company ended the quarter with 201 U.S. live revenue-generating instruments and an additional 213 contracted but not live instruments. However, the net loss stood at $19.2 million, or $0.35 per share. The gross margin decreased to 45% from 50% due to lower overhead absorption. The company launched the PhenoAST Test and plans to launch the PhenoPrep instrument in Q1 2021, bolstering its product portfolio amidst pandemic-related challenges.